
Therapeutic Goods (Exempt Monographs) Determination 2021
made under section 3C of the
Therapeutic Goods Act 1989
Compilation No. 4
Compilation date: 3 July 2025
Includes amendments: F2025L00800
About this compilation
This compilation
This is a compilation of the Therapeutic Goods (Exempt Monographs) Determination 2021 that shows the text of the law as amended and in force on 3 July 2025 (the compilation date).
The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.
Uncommenced amendments
The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the Register for the compiled law.
Application, saving and transitional provisions for provisions and amendments
If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.
Modifications
If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the Register for the compiled law.
Self‑repealing provisions
If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.
1 Name
3 Authority
4 Definitions
5 Exemption of entire monographs
6 Exemption of parts of monographs
Schedule 1—Exempt monographs
Schedule 2—Exempt parts of monographs
Endnotes
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
This instrument is the Therapeutic Goods (Exempt Monographs) Determination 2021.
This instrument is made under section 3C of the Therapeutic Goods Act 1989.
Note: A number of expressions used in this instrument are defined in subsection 3(1) of the Act, including the following:
(a) British Pharmacopoeia;
(b) European Pharmacopoeia;
(c) export only medicine;
(d) listed goods;
(e) medicine;
(f) Register;
(g) standard;
(h) therapeutic goods;
(i) United States Pharmacopeia-National Formulary.
In this instrument:
Act means the Therapeutic Goods Act 1989.
For subsection 3C(1) of the Act, in relation to each item mentioned in the table in Schedule 1, the monographs specified in column 2, in the pharmacopoeia specified in column 3, are exempt for the purposes of paragraph (b), (c) or (d) of the definition of standard in subsection 3(1) of the Act, in relation to the therapeutic goods specified in column 4.
For subsection 3C(2) of the Act, in relation to each item mentioned in the table in Schedule 2, the statements in monographs specified in column 2, in the pharmacopoeia specified in column 3, are exempt for the purposes of paragraph (b), (c) or (d) of the definition of standard in subsection 3(1) of the Act, in relation to the therapeutic goods specified in column 4.
Note: See section 5.
Monographs exempt from the definition of standard | ||||
Column 1 | Column 2 | Column 3 | Column 4 | |
Item | Monograph | Pharmacopoeia | Therapeutic goods | |
antithrombin III human | United States Pharmacopeia-National Formulary | therapeutic goods | ||
3 | factor IX complex | United States Pharmacopeia-National Formulary | therapeutic goods | |
4 | pancreatin | United States Pharmacopeia-National Formulary | therapeutic goods | |
5 | pancrelipase | United States Pharmacopeia-National Formulary | therapeutic goods | |
6 | plasma protein fraction | United States Pharmacopeia-National Formulary | therapeutic goods | |
Note: See section 6.
Parts of monographs exempt from the definition of standard | ||||
Column 1 | Column 2 | Column 3 | Column 4 | |
Item | Statements in monographs | Pharmacopoeia | Therapeutic goods | |
1 | the statement in monograph 3053 that the label states the name of any stabilisers and other excipients | each of the following: (a) British Pharmacopoeia; (b) European Pharmacopoeia | medicines that: (a) are listed goods or eligible for listing, other than export only medicines; and (b) contain a whole live microorganism, other than arthrospira maxima or arthrospira platensis, as an active ingredient | |
The endnotes provide information about this compilation and the compiled law.
The following endnotes are included in every compilation:
Endnote 1—About the endnotes
Endnote 2—Abbreviation key
Endnote 3—Legislation history
Endnote 4—Amendment history
Abbreviation key—Endnote 2
The abbreviation key sets out abbreviations that may be used in the endnotes.
Legislation history and amendment history—Endnotes 3 and 4
Amending laws are annotated in the legislation history and amendment history.
The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.
The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.
Misdescribed amendments
A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.
If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.
ad = added or inserted | orig = original |
am = amended | par = paragraph(s)/subparagraph(s) |
amdt = amendment | /sub‑subparagraph(s) |
c = clause(s) | pres = present |
C[x] = Compilation No. x | prev = previous |
Ch = Chapter(s) | (prev…) = previously |
def = definition(s) | Pt = Part(s) |
Dict = Dictionary | r = regulation(s)/rule(s) |
disallowed = disallowed by Parliament | reloc = relocated |
Div = Division(s) | renum = renumbered |
exp = expires/expired or ceases/ceased to have | rep = repealed |
effect | rs = repealed and substituted |
F = Federal Register of Legislation | s = section(s)/subsection(s) |
gaz = gazette | Sch = Schedule(s) |
LA = Legislation Act 2003 | Sdiv = Subdivision(s) |
LIA = Legislative Instruments Act 2003 | SLI = Select Legislative Instrument |
(md not incorp) = misdescribed amendment | SR = Statutory Rules |
cannot be given effect | Sub‑Ch = Sub‑Chapter(s) |
mod = modified/modification | SubPt = Subpart(s) |
No. = Number(s) | underlining = whole or part not |
o = order(s) | commenced or to be commenced |
Ord = Ordinance |
|
Name | Registration | Commencement | Application, saving and transitional provisions |
Therapeutic Goods (Exempt Monographs) Determination 2021 | 19 May 2021 (F2021L00594) | 01 Oct 2021 | — |
Therapeutic Goods (Exempt Monographs) Amendment Determination 2022 | 28 Mar 2022 (F2022L00401) | 31 Mar 2022 | — |
Therapeutic Goods (Standard for Nicotine Vaping Products) (TGO 110) Amendment (Vaping) Order 2023 | 15 Dec 2023 (F2023L01680) | 01 Jan 2024 | — |
Therapeutic Goods Legislation Amendment (Standard for Therapeutic Vaping Goods) (TGO 110) Instrument 2024 | 30 Sep 2024 (F2024L01232) | 01 Oct 2024 | — |
Therapeutic Goods (Exempt Monographs) Amendment Determination 2025 | 2 Jul 2025 (F2025L00800) | 3 Jul 2025 | — |
Provision affected | How affected |
s 2………………………………. | rep LA s 48D |
s 4………………………………. | am F2023L01680; F2024L01232, F2025L00800 |
s 5………………………………. | am F2025L00800 |
s 6………………………………. | ad F2025L00800 |
Schedule 1……………………… | am F2022L00401; F2023L01680; F2024L01232 |
Schedule 2……………………… | ad F2025L00800 |